2Seventy Bio Inc Net Assets

Latest as of March 2025: $213.96 Million USD

2Seventy Bio Inc net assets. Based on the latest financial reports, 2Seventy Bio Inc (TSVT) has net assets worth $213.96 Million USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($480.00 Million) and total liabilities ($266.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 2Seventy Bio Inc (TSVT) equity growth momentum to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric Value
Current Net Assets $213.96 Million
% of Total Assets 44.57%
Annual Growth Rate 36.97%
5-Year Change 182.47%
10-Year Change N/A
Growth Volatility 154.41

Net Assets of 2Seventy Bio Inc (2019–2024)

Net assets of 2Seventy Bio Inc from 2019 to 2024. This chart illustrates how 2Seventy Bio Inc's net assets have evolved over time, based on quarterly financial data. See 2Seventy Bio Inc net asset quality index to measure how much of total assets are equity-financed.

Annual Net Assets for 2Seventy Bio Inc (2019–2024)

The table below shows the annual net assets of 2Seventy Bio Inc from 2019 to 2024. For live market cap and overall valuation, see TSVT market cap overview.

Year Net Assets Change
2024-12-31 $210.81 Million -17.43%
2023-12-31 $255.30 Million -17.77%
2022-12-31 $310.47 Million -13.72%
2021-12-31 $359.82 Million +382.15%
2020-12-31 $74.63 Million +70.81%
2019-12-31 $43.69 Million --

Equity Component Analysis

This analysis shows how different components contribute to 2Seventy Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 56846400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

2Seventy Bio Inc Net Assets Breakdown (December 2024)

2Seventy Bio Inc net assets breakdown by equity component as of December 2024.

Component Amount Percentage
Common Stock $5.00K 0.00%
Other Comprehensive Income $89.00K 0.04%
Other Components $779.18 Million 369.62%
Total Equity $210.81 Million 100.00%

2Seventy Bio Inc Competitors by Market Cap

The table below lists competitors of 2Seventy Bio Inc ranked by their market capitalization.

Company Market Cap
Panama Petrochem Limited
NSE:PANAMAPET
$266.30 Million
Zhejiang Golden Eagle Co Ltd
SHG:600232
$266.32 Million
Beijing Sanfo Outdoor Products Co Ltd
SHE:002780
$266.42 Million
Vox Royalty Corp.
TO:VOXR
$266.44 Million
Taeyoung Engineering & Construction Co.,Ltd.
KO:009415
$266.07 Million
Kenmare Resources PLC
IR:KMR
$266.05 Million
SuRo Capital Corp
NASDAQ:SSSS
$265.92 Million
Harbin Air Conditioning Co Ltd
SHG:600202
$265.89 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in 2Seventy Bio Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 255,300,000 to 210,806,000, a change of -44,494,000 (-17.4%).
  • Net loss of 57,247,000 reduced equity.
  • Other comprehensive income increased equity by 293,000.
  • Other factors increased equity by 12,460,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $-57.25 Million -27.16%
Other Comprehensive Income $293.00K +0.14%
Other Changes $12.46 Million +5.91%
Total Change $- -17.43%

Book Value vs Market Value Analysis

This analysis compares 2Seventy Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.24x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 2.66x to 1.24x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2019-12-31 $1.88 $5.00 x
2020-12-31 $3.20 $5.00 x
2021-12-31 $15.26 $5.00 x
2022-12-31 $8.71 $5.00 x
2023-12-31 $5.18 $5.00 x
2024-12-31 $4.04 $5.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently 2Seventy Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -27.16%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -151.20%
  • • Asset Turnover: 0.08x
  • • Equity Multiplier: 2.27x
  • Recent ROE (-27.16%) is above the historical average (-200.11%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2019 -740.05% -729.96% 0.14x 7.21x $-327.71 Million
2020 -185.14% -55.69% 0.79x 4.19x $-145.63 Million
2021 -81.21% -535.95% 0.07x 2.11x $-328.20 Million
2022 -81.86% -277.77% 0.14x 2.12x $-285.19 Million
2023 -85.22% -216.73% 0.18x 2.21x $-243.10 Million
2024 -27.16% -151.20% 0.08x 2.27x $-78.33 Million

Industry Comparison

This section compares 2Seventy Bio Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $99,768,208
  • Average return on equity (ROE) among peers: -27.40%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
2Seventy Bio Inc (TSVT) $213.96 Million -740.05% 1.24x $266.14 Million
Aardvark Therapeutics, Inc. Common Stock (AARD) $-34.80 Million 0.00% 0.00x $20.09 Million
Abcellera Biologics Inc (ABCL) $10.25 Million -21.57% 1.29x $3.16 Billion
Abeona Therapeutics Inc (ABEO) $-14.78 Million 0.00% 0.00x $138.39 Million
Acumen Pharmaceuticals Inc (ABOS) $225.18 Million -44.68% 0.02x $13.47 Million
Abpro Holdings, Inc. (ABP) $-22.46 Million 0.00% 0.00x $2.00 Million
Absci Corp (ABSI) $-41.16 Million 0.00% 0.00x $1.29 Billion
Arbutus Biopharma Corp (ABUS) $200.23 Million -28.52% 0.14x $796.39 Million
ABVC Biopharma Inc (ABVC) $29.08K -111.02% 1.35x $23.09 Million
Abivax SA American Depositary Shares (ABVX) $48.18 Million -23.29% 0.12x $6.41 Billion
ACADIA Pharmaceuticals Inc (ACAD) $627.01 Million -44.91% 0.25x $2.95 Billion

About 2Seventy Bio Inc

NASDAQ:TSVT USA Biotechnology
Market Cap
$266.14 Million
Market Cap Rank
#14763 Global
#3562 in USA
Share Price
$5.00
Change (1 day)
+0.00%
52-Week Range
$5.00 - $5.00
All Time High
$42.56
About

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was inco… Read more